The
GE HealthCare Technologies Inc (GEHC) stock experienced impressive growth as
Institutional ownership increased,
Wright Investors Service Inc., Creative Planning, and AQR Capital Management LLC all acquired substantial shares. The stock was deemed a good portfolio holder by investment analysts and hedge funds revealed bullish tendencies towards the healthcare technology firm.
JP Morgan provided neutral coverage and the healthcare stock's
undervaluation was highlighted as an opportunity for investors. However, there were concerns about key pressure points and potential risks.
Secondary offerings of up to
15M shares were launched, with the stock's price rising post-FDA approval of
Flyrcado. Artificial Intelligence (AI) was a strong feature as the launch of the
AI-Powered Venue Sprint pushed shares higher. Meanwhile, the company faced negative feedback such as a downgrade to 'sell' by
UBS regarding Chinese competition and missed quarterly revenue estimates, yet still enjoyed strong institutional backing.
Buy upgrades were issued by
BTIG, and dividends were announced for Q2 and Q3 of 2024. Despite a revenue miss and guidance cut, Q2 earnings beat estimates with a noticeable margin increase.
Ge Healthcare Technologies GEHC News Analytics from Tue, 13 Feb 2024 08:00:00 GMT to Sun, 06 Oct 2024 00:40:59 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor -3
